Sharon Laughlin, MD
Family Practice · Riverside, CANPI 1689638348
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,045 of the $7,598 with a category attached, or 79.6%. 24 manufacturers reported payments, led by Biohaven Pharmaceutical Holding Company Ltd. at 26.0% of the total. Among family practice clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $30.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- AstraZeneca$1K
- Boehringer Ingelheim$701
- AbbVie$509
- Lilly USA, LLC$440
- Pfizer$418
- plus $2K from 18 others
What the payments were for
- Consulting fees$1,20016%
- Travel & lodging$3334%
- Food & beverage$6,04580%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $1,978 |
| AstraZeneca | 41 | $1,067 |
| Boehringer Ingelheim | 27 | $701 |
| AbbVie(2 entities) | 30 | $509 |
| Lilly USA, LLC | 11 | $440 |
| Pfizer | 24 | $418 |
| Novo Nordisk | 12 | $370 |
| GSK | 11 | $310 |
| Amgen | 12 | $242 |
| E.r. Squibb & Sons, L.L.C. | 6 | $210 |
| Corcept Therapeutics | 13 | $205 |
| Johnson & Johnson | 12 | $188 |
| Merck | 8 | $165 |
| Bayer | 6 | $160 |
| Biohaven Pharmaceuticals, Inc. | 2 | $139 |
| Exact Sciences | 8 | $134 |
| Eisai Inc. | 5 | $100 |
| Abbott | 4 | $83 |
| Intuitive Surgical | 1 | $57 |
| Merz North America, Inc. | 2 | $34 |
| Averitas Pharma Inc. | 1 | $30 |
| Therapeuticsmd, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,598 in reported general payments places this provider in the 95th percentile of 2,195 family practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 119 | $104,771 |
| OzempicSemaglutide | 65 | $72,914 |
| FarxigaDapagliflozin Propanediol | 63 | $56,496 |
| XareltoRivaroxaban | 46 | $44,619 |
| JardianceEmpagliflozin | 38 | $43,480 |
| JanuviaSitagliptin Phosphate | 27 | $36,393 |
| MounjaroTirzepatide | 17 | $25,579 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $15,181 |
| MyrbetriqMirabegron | 14 | $12,964 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $11,277 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,072 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $6,334 |
| Colesevelam Hcl | 12 | $5,835 |
| Atorvastatin Calcium | 471 | $4,930 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $4,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $418 | $104,771119 claims |
| Novo NordiskOzempic | $370 | $72,91465 claims |
| AstraZenecaFarxiga | $1,067 | $56,49663 claims |
| Johnson & JohnsonXarelto | $188 | $44,61946 claims |
| Boehringer IngelheimJardiance | $701 | $43,48038 claims |
| MerckJanuvia | $165 | $36,39327 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $310 | $26,45942 claims |
| Lilly USA, LLCMounjaro | $440 | $25,57917 claims |
| AbbVieSynthroid | $509 | $2,37627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,195 family practice providers in California.
Other family practice in Riverside
- Kacie PaikRiverside$163
- David CahnSan Jose$40K
- Linh NguyenSan Jose$15K
- Paige YoshisatoVallejo$14K
- Boris VaismanWoodland Hills$11K
- Michael KanLos Gatos$4K
- Claudia CarranzaBakersfield$4K
- Sunil HebbarHermosa Beach$3K
- Monica SuNewbury Park$3K
- Taraneh MatinPasadena$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.